subscribeSubscribe
Nabriva hit with 2nd FDA complete response letter for Contepo

Nabriva hit with 2nd FDA complete response letter for Contepo
K. Blankenship FIERCE PHARMA
23 Jun 2020
Share Share
Nabriva Receives Complete Response Letter from FDA on NDA for (fosfomycin)

Nabriva Receives Complete Response Letter from FDA on NDA for (fosfomycin)
BIOSPACE
21 Jun 2020
Share Share
Recommendations to restrict use of fosfomycin antibiotics

Recommendations to restrict use of fosfomycin antibiotics
EMA
27 Mar 2020
Share Share
Add Interquim Project: PCS7 updating project in a regulated Pharma environment

Add Interquim Project: PCS7 updating project in a regulated Pharma environment
PRESS RELEASE
02 Mar 2020
Share Share
Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission

Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission
GLOBE NEWSWIRE
08 Jan 2020
Share Share
Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission

Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission
GLOBE NEWSWIRE
07 Jan 2020
Share Share
Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission

Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission
GLOBE NEWSWIRE
07 Jan 2020
Share Share
Nabriva Therapeutics Resubmits NDA for Intravenous fosfomycin for Injection

Nabriva Therapeutics Resubmits NDA for Intravenous fosfomycin for Injection
GLOBENEWS WIRE
20 Dec 2019
Share Share
Meeting highlights from the CHMP 10-13 December 2018

Meeting highlights from the CHMP 10-13 December 2018
14 Dec 2018
Share Share
Nabriva snaps up Zavante for its market-ready antibiotic

Nabriva snaps up Zavante for its market-ready antibiotic
GlobalData Healthcare PHARMA TECH
02 Aug 2018
Share Share